EA202190718A1 - Индазолкарбоксамиды в качестве ингибиторов киназ - Google Patents

Индазолкарбоксамиды в качестве ингибиторов киназ

Info

Publication number
EA202190718A1
EA202190718A1 EA202190718A EA202190718A EA202190718A1 EA 202190718 A1 EA202190718 A1 EA 202190718A1 EA 202190718 A EA202190718 A EA 202190718A EA 202190718 A EA202190718 A EA 202190718A EA 202190718 A1 EA202190718 A1 EA 202190718A1
Authority
EA
Eurasian Patent Office
Prior art keywords
indazol
carboxamides
kinase inhibitors
ripk1
soli
Prior art date
Application number
EA202190718A
Other languages
English (en)
Inventor
Цзюньцин Го
Цзе Чэнь
Кэролин Дайан Дзирба
Эми С. Харт
Гуанлин Луо
Джон Е. Макор
Уильям Дж. Питтс
Синг-Юэнь Сит
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA202190718A1 publication Critical patent/EA202190718A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Соединения формулы (I) и их энантиомеры и диастереомеры, стереоизомеры, фармацевтически приемлемые солиприменимы в качестве модуляторов киназы, включая модуляцию RIPK1. Все переменные определены в настоящем изобретении.
EA202190718A 2018-09-13 2019-09-12 Индазолкарбоксамиды в качестве ингибиторов киназ EA202190718A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862730602P 2018-09-13 2018-09-13
PCT/US2019/050719 WO2020056072A1 (en) 2018-09-13 2019-09-12 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)

Publications (1)

Publication Number Publication Date
EA202190718A1 true EA202190718A1 (ru) 2021-07-01

Family

ID=68073171

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190718A EA202190718A1 (ru) 2018-09-13 2019-09-12 Индазолкарбоксамиды в качестве ингибиторов киназ

Country Status (14)

Country Link
US (1) US20220380335A1 (ru)
EP (1) EP3849968B1 (ru)
JP (1) JP2022500418A (ru)
KR (1) KR20210060517A (ru)
CN (1) CN112673000B (ru)
AU (1) AU2019337612A1 (ru)
BR (1) BR112021004385A2 (ru)
CA (1) CA3112735A1 (ru)
EA (1) EA202190718A1 (ru)
ES (1) ES2936481T3 (ru)
IL (1) IL281370A (ru)
MX (1) MX2021002509A (ru)
SG (1) SG11202102405YA (ru)
WO (1) WO2020056072A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220297T1 (hr) 2017-10-30 2022-05-13 Bristol-Myers Squibb Company Aminoimidazopiridazini kao inhibitori kinaze
US11618753B2 (en) 2018-01-26 2023-04-04 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
SG11202102406XA (en) 2018-09-13 2021-04-29 Bristol Myers Squibb Co Indazole carboxamides as kinase inhibitors
JP2022552158A (ja) * 2019-10-03 2022-12-15 ブリストル－マイヤーズ スクイブ カンパニー キナーゼ阻害剤としてのインダゾールカルボキサミド
JP2023541464A (ja) * 2020-09-15 2023-10-02 ファースト・バイオセラピューティクス・インコーポレイテッド ２－アミノ－３－カルボニルイミダゾピリジン及びピラゾロピリジン化合物
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2759083A1 (en) * 2009-04-30 2010-11-04 Novartis Ag Imidazole derivatives and their use as modulators of cyclin dependent kinases
KR20130077390A (ko) * 2011-12-29 2013-07-09 제이더블유중외제약 주식회사 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체
WO2014047024A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Iap antagonists
US9546153B2 (en) * 2012-11-08 2017-01-17 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
SG11202102406XA (en) * 2018-09-13 2021-04-29 Bristol Myers Squibb Co Indazole carboxamides as kinase inhibitors

Also Published As

Publication number Publication date
ES2936481T3 (es) 2023-03-17
CN112673000A (zh) 2021-04-16
EP3849968A1 (en) 2021-07-21
JP2022500418A (ja) 2022-01-04
WO2020056072A1 (en) 2020-03-19
BR112021004385A2 (pt) 2021-07-20
MX2021002509A (es) 2021-04-28
CA3112735A1 (en) 2020-03-19
US20220380335A1 (en) 2022-12-01
IL281370A (en) 2021-04-29
KR20210060517A (ko) 2021-05-26
EP3849968B1 (en) 2022-12-21
AU2019337612A1 (en) 2021-05-13
CN112673000B (zh) 2024-10-18
SG11202102405YA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
EA202190759A1 (ru) Индазолкарбоксамиды в качестве ингибиторов киназ
EA202190718A1 (ru) Индазолкарбоксамиды в качестве ингибиторов киназ
EA201991915A1 (ru) Аминотриазолопиридины в качестве ингибиторов киназ
EA202091506A1 (ru) Триазол n-связанные карбамоил циклогексильные кислоты в качестве антагонистов lpa
MX2022005827A (es) Derivados de pirazol como inhibidores de malt1.
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
MX2021010198A (es) Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
EA201691302A1 (ru) Новые гетероциклические соединения
EA202091777A1 (ru) Аминопирролотриазины в качестве ингибиторов киназы
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
EA201792214A1 (ru) Соединения замещенного хиназолина
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2017014809A (es) Amidas heterociclicas como inhibidores de cinasa.
EA202191519A1 (ru) Модуляторы trex1
EA202091063A1 (ru) Мостиковые бициклические соединения в качестве модуляторов фарнезоидного х-рецептора
EA201991884A2 (ru) Ингибиторы g12c kras
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
CY1124984T1 (el) Αμινοïμιδαζοπυριδινες ως αναστολεις κινασων
EA202092962A1 (ru) Производные пиразола в качестве ингибиторов malt1
EA201792478A1 (ru) Соединения-ингибиторы передачи сигналов пути notch
MX2022003769A (es) Indazol carboxamidas como inhibidores de cinasas.
EA202190395A1 (ru) Замещенные гетероарилом сульфонамидные соединения и их применение в качестве терапевтических средств
EA202190055A1 (ru) Производные пиразола в качестве ингибиторов malt1
EA201992409A1 (ru) Ингибиторы magl на основе пиразола
MX2021001565A (es) Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad).